Literature DB >> 25185630

Minimum important differences for scales assessing symptom severity and quality of life in patients with fecal incontinence.

John Eric Jelovsek1, Zhen Chen, Alayne D Markland, Linda Brubaker, Keisha Y Dyer, Susie Meikle, David D Rahn, Nazeema Y Siddiqui, Ashok Tuteja, Matthew D Barber.   

Abstract

OBJECTIVES: The objective of this study was to estimate the minimum important difference (MID) for the Fecal Incontinence Severity Index (FISI), the Colorectal-Anal Distress Inventory (CRADI) scale of the Pelvic Floor Distress Inventory, the Colorectal-Anal Impact Questionnaire (CRAIQ) scale of the Pelvic Floor Impact Questionnaire, and the Modified Manchester Health Questionnaire (MMHQ).
METHODS: We calculated the MIDs using anchor-based and distribution-based approaches from a multicenter prospective cohort study investigating adaptive behaviors among women receiving nonsurgical and surgical management for fecal incontinence (FI). Patient responses were primarily anchored using a Global Impression of Change scale. The MID was defined as the difference in mean change from baseline between those who indicated they were "a little better" and those who reported "no change" on the Global Impression of Change scale 3 months after treatment. The effect size and SE of measurement were the distribution methods used.
RESULTS: The mean changes (SD) in FISI, CRADI, CRAIQ, and MMHQ scores from baseline to 3 months after treatment were -8.8 (12.0), -52.7 (70.0), -60.6 (90.0), and -12.6 (19.2), respectively. The anchor-based MID estimates suggested by an improvement from no change to a little better were -3.6, -11.4 and -4.7, -18.1 and -8.0, and -3.2 for the FISI, CRADI (long and short version), CRAIQ (long and short version), and MMHQ, respectively. These data were supported by 2 distribution-based estimates.
CONCLUSIONS: The MID values for the FISI are -4, CRADI (full version, -11; short version, -5), CRAIQ (full version, -18; short version, -8), and MMHQ -3. Statistically significant improvements that meet these thresholds are likely to be clinically important.

Entities:  

Mesh:

Year:  2014        PMID: 25185630      PMCID: PMC4213305          DOI: 10.1097/SPV.0000000000000078

Source DB:  PubMed          Journal:  Female Pelvic Med Reconstr Surg        ISSN: 2151-8378            Impact factor:   2.091


  20 in total

1.  Linking clinical relevance and statistical significance in evaluating intra-individual changes in health-related quality of life.

Authors:  K W Wyrwich; N A Nienaber; W M Tierney; F D Wolinsky
Journal:  Med Care       Date:  1999-05       Impact factor: 2.983

Review 2.  Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation.

Authors:  Geoffrey R Norman; Jeff A Sloan; Kathleen W Wyrwich
Journal:  Med Care       Date:  2003-05       Impact factor: 2.983

3.  Defining clinically meaningful change in health-related quality of life.

Authors:  Ross D Crosby; Ronette L Kolotkin; G Rhys Williams
Journal:  J Clin Epidemiol       Date:  2003-05       Impact factor: 6.437

4.  Prospective comparison of faecal incontinence grading systems.

Authors:  C J Vaizey; E Carapeti; J A Cahill; M A Kamm
Journal:  Gut       Date:  1999-01       Impact factor: 23.059

5.  Patient and surgeon ranking of the severity of symptoms associated with fecal incontinence: the fecal incontinence severity index.

Authors:  T H Rockwood; J M Church; J W Fleshman; R L Kane; C Mavrantonis; A G Thorson; S D Wexner; D Bliss; A C Lowry
Journal:  Dis Colon Rectum       Date:  1999-12       Impact factor: 4.585

6.  Further validation of the short form versions of the Pelvic Floor Distress Inventory (PFDI) and Pelvic Floor Impact Questionnaire (PFIQ).

Authors:  Matthew D Barber; Zhen Chen; Emily Lukacz; Alayne Markland; Clifford Wai; Linda Brubaker; Ingrid Nygaard; Alison Weidner; Nancy K Janz; Cathie Spino
Journal:  Neurourol Urodyn       Date:  2011-02-22       Impact factor: 2.696

7.  Measuring change over time: assessing the usefulness of evaluative instruments.

Authors:  G Guyatt; S Walter; G Norman
Journal:  J Chronic Dis       Date:  1987

8.  Psychometric evaluation of 2 comprehensive condition-specific quality of life instruments for women with pelvic floor disorders.

Authors:  M D Barber; M N Kuchibhatla; C F Pieper; R C Bump
Journal:  Am J Obstet Gynecol       Date:  2001-12       Impact factor: 8.661

Review 9.  Methods to explain the clinical significance of health status measures.

Authors:  Gordon H Guyatt; David Osoba; Albert W Wu; Kathleen W Wyrwich; Geoffrey R Norman
Journal:  Mayo Clin Proc       Date:  2002-04       Impact factor: 7.616

10.  Health-related quality of life measures for women with urinary incontinence: the Incontinence Impact Questionnaire and the Urogenital Distress Inventory. Continence Program in Women (CPW) Research Group.

Authors:  S A Shumaker; J F Wyman; J S Uebersax; D McClish; J A Fantl
Journal:  Qual Life Res       Date:  1994-10       Impact factor: 4.147

View more
  18 in total

Review 1.  Posterior vaginal compartment prolapse and defecatory dysfunction: are they related?

Authors:  Cara L Grimes; Emily S Lukacz
Journal:  Int Urogynecol J       Date:  2012-01-06       Impact factor: 2.894

2.  Adverse events of sacral neuromodulation for fecal incontinence reported to the federal drug administration.

Authors:  Klaus Bielefeldt
Journal:  World J Gastrointest Pharmacol Ther       Date:  2016-05-06

3.  Symptom improvement in women after fecal incontinence treatments: a multicenter cohort study of the pelvic floor disorders network.

Authors:  Alayne Markland; Lu Wang; J Eric Jelovsek; Linda Brubaker; Ashook Tuteja; Alison C Weidner; Andelka LoSavio; Marlene Corton; Susan Meikle; Holly E Richter
Journal:  Female Pelvic Med Reconstr Surg       Date:  2015 Jan-Feb       Impact factor: 2.091

4.  Controlling faecal incontinence in women by performing anal exercises with biofeedback or loperamide: a randomised clinical trial.

Authors:  J Eric Jelovsek; Alayne D Markland; William E Whitehead; Matthew D Barber; Diane K Newman; Rebecca G Rogers; Keisha Dyer; Anthony G Visco; Gary Sutkin; Halina M Zyczynski; Benjamin Carper; Susan F Meikle; Vivian W Sung; Marie G Gantz
Journal:  Lancet Gastroenterol Hepatol       Date:  2019-07-15

5.  Effect of Uterosacral Ligament Suspension vs Sacrospinous Ligament Fixation With or Without Perioperative Behavioral Therapy for Pelvic Organ Vaginal Prolapse on Surgical Outcomes and Prolapse Symptoms at 5 Years in the OPTIMAL Randomized Clinical Trial.

Authors:  J Eric Jelovsek; Matthew D Barber; Linda Brubaker; Peggy Norton; Marie Gantz; Holly E Richter; Alison Weidner; Shawn Menefee; Joseph Schaffer; Norma Pugh; Susan Meikle
Journal:  JAMA       Date:  2018-04-17       Impact factor: 56.272

6.  PELVIC FLOOR SYMPTOMS AND QUALITY OF LIFE ANALYSES IN WOMEN UNDERGOING SURGERY FOR RECTAL PROLPASE.

Authors:  Dr Ellington; M Mann; Cb Bowling; Er Drelichman; Wj Greer; Jm Szychowski; He Richter
Journal:  World J Colorectal Surg       Date:  2013-12

7.  Fecal Incontinence Symptoms and Impact in Older Versus Younger Women Seeking Care.

Authors:  Isuzu Meyer; Christina T Blanchard; Alayne D Markland; Elena G Gibson; Holly E Richter
Journal:  Dis Colon Rectum       Date:  2019-06       Impact factor: 4.585

Review 8.  Endpoints for therapeutic interventions in faecal incontinence: small step or game changer.

Authors:  S S C Rao
Journal:  Neurogastroenterol Motil       Date:  2016-08       Impact factor: 3.598

9.  Pelvic Floor and Urinary Distress in Women with Fibromyalgia.

Authors:  Kim Dupree Jones; Charlene Maxwell; Scott D Mist; Virginia King; Mary Anna Denman; W Thomas Gregory
Journal:  Pain Manag Nurs       Date:  2015-08-08       Impact factor: 1.929

10.  Tools for fecal incontinence assessment: lessons for inflammatory bowel disease trials based on a systematic review.

Authors:  Ferdinando D'Amico; Steven D Wexner; Carolynne J Vaizey; Célia Gouynou; Silvio Danese; Laurent Peyrin-Biroulet
Journal:  United European Gastroenterol J       Date:  2020-07-17       Impact factor: 4.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.